Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy (Secura)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00916643
Recruitment Status : Completed
First Posted : June 9, 2009
Results First Posted : January 29, 2014
Last Update Posted : March 4, 2014
Information provided by (Responsible Party):
B. Braun Medical Inc.

Brief Summary:

The objectives of this post-surveillance study are to continue to evaluate the safety and effectiveness of the H.E.L.P. System. The safety and effectiveness will be assessed by evaluating the occurrence of death, cardiovascular events or interventions, angina, and serious unanticipated adverse effects. Laboratory assessments will be made to document low-density lipoprotein cholesterol (LDL-C) reduction and any effects on other blood components. Quality of life assessments will also be made.

The study will also assess the modifications to the H.E.L.P. System, including:

  • use of a single heparin adsorber, instead of two smaller adsorbers;
  • change in the supplier of the ultrafilter (from Secon to Toray);
  • reduction in the number of blood lines from eleven to nine;
  • change from a single-layer to a two-layer precipitate filter.

The safety and efficacy of the device specific to these modifications will be evaluated by comparing the safety and efficacy data from the patient registry to the data from the initial clinical study on the device as originally designed.

Condition or disease Intervention/treatment Phase
Familial Hypercholesterolemia Device: HELP Secura (apheresis treatment) Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 113 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy
Study Start Date : December 1999
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: H.E.L.P. Secura

The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:

  1. Flushing the system with normal saline.
  2. Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.
  3. Mixing the plasma with an equal volume of acetate buffer containing heparin.
  4. Precipitation of LDL as a complex with heparin.
  5. Removing the LDL-heparin precipitate by continuous circulation through a filter.
  6. Removing heparin with use of a heparin adsorber.
  7. Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.
  8. Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient.
Device: HELP Secura (apheresis treatment)
Process is described in Arm (above).

Primary Outcome Measures :
  1. Occurence of Death [ Time Frame: Participants were followed for one (1) year following discontinuation of treatment. ]
    The Categories listed in the table are the Adverse Events (or similar) that resulted in death.

  2. Occurrence of Cardiovascular Events and Interventions [ Time Frame: Participants were followed for one (1) year following discontinuation of treatment. ]
    Adverse Events reported for Cardiovascular disease not directly related to therapy.

  3. Serious Unexpected Adverse Events [ Time Frame: Participants were followed for one (1) year following discontinuation of treatment. ]
  4. Frequency and Severity of CHD Symptoms (Angina) [ Time Frame: Participants were followed for one (1) year following discontinuation of treatment. ]
    This is equatable to the incidence of Cardiovascular AEs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adequate venous access
  • Laboratory values:

    • Hematocrit 30% or greater
    • platelet count between 100,000 and 1,000,000/ml
  • Premenopausal women must be surgically sterilized or be on oral contraceptive therapy and have a negative pregnancy test at the onset of treatment with H.E.L.P.
  • Patients have familial hypercholesterolemia and have undergone at least 6 months optimal diet and drug therapy and fit group A, B, or C

Exclusion Criteria:

  • Presence of any of the following conditions:

    • untreated hypothyroidism
    • decompensated congestive heart failure
    • major arrhythmia
    • uncontrolled diabetes mellitus
    • any malignancy
    • disorders associated with excessive bleeding (e.g., peptic ulcer and hemophilia)
    • established or suspected intracranial disease which might cause intracranial bleeding if the patient is anticoagulated
    • any other medical disorders which lead the treating physician to believe that H.E.L.P. treatment would not be in the best interest of the patient
    • current treatment with anticoagulants
    • diastolic BP > 100 mmHg recorded in two occasions at least 24 hours apart.
    • patients under 18 years of age
    • positive test for Hepatitis [Type A (IgM) or B] antigen, Hepatitis C antibody, or HIV (or diagnosis of AIDS)

Layout table for additonal information
Responsible Party: B. Braun Medical Inc. Identifier: NCT00916643    
Other Study ID Numbers: BBMI_HELP_Secura
First Posted: June 9, 2009    Key Record Dates
Results First Posted: January 29, 2014
Last Update Posted: March 4, 2014
Last Verified: January 2014
Keywords provided by B. Braun Medical Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type II
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP3A Inhibitors